Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| TAK-875 | TAK-875 is a potent, selective, and orally bioavailable GPR40 agonist, with a pharmacokinetic profile enabling long-acting drug efficacy. Synonyms: TAK875; TAK 875; Fasiglifam; 3-Benzofuranacetic acid, 6-[[2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-, (3S)-; (3S)-6-[[2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid; (+)-TAK 875; (3S)-6-([2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl]methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid. Grades: >98%. CAS No. 1000413-72-8. Molecular formula: C29H32O7S. Mole weight: 524.63. |  |
| TAK-875 Hemihydrate | TAK-875 is a novel, orally available, selective GPR40 agonist. TAK-875 exhibits potent agonist activity and high binding affinity to the human GPR40 receptor with Ki of 38 nM. TAK-875 enhanced glucose-induced insulin secretion in a glucose-dependent manner in both human and rat islets. In rat insulinoma INS-1 833/15 cells, TAK-875 increased intracellular inositol monophosphate and calcium concentration, consistent with activation of the Gqα signaling pathway. In addition, TAK-875 (10 mg/kg, p.o.) significantly augmented plasma insulin levels and reduced fasting hyperglycemia in male Zucker diabetic fatty rats, whereas in fasted normal Sprague-Dawley rats, TAK-875 neither enhanced insulin secretion nor caused hypoglycemia even at 30 mg/kg. TAK-875 improves both postprandial and fasting hyperglycemia with a low risk of hypoglycemia and no evidence of β cell toxicity. TAK-875 significantly improved glycaemic control in patients with type 2 diabetes with minimum risk of hypoglycaemia. Synonyms: Fasiglifam hemihydrate; TAK875 hemihydrate; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) biphenyl-3-yl)methoxy)-2,3-dihydro-l-benzofuran-3-yl)acetic acid hemihydrate. Grades: 98%. CAS No. 1374598-80-7. Molecular formula: C58H66O15S2. Mole weight: 1067.27. | |
| Fasiglifam | Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC 50 of 72 nM. Uses: Scientific research. Group: Signaling pathways. Alternative Names: TAK-875. CAS No. 1000413-72-8. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-10480. |  |
| Tak875 | Tak875. Uses: Designed for use in research and industrial production. Additional or Alternative Names: TAK875;3-Benzofuranacetic acid, 6-[[2,6-diMethyl-4-[3-(Methylsulfonyl)propoxy][1,1-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-;(3S)-6-[[2,6-Dimethyl-4-[3-(methylsulfonyl)propoxy][1,1-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid;TAK-875,TAK875;[(3S)-6-({2,6-Dimethyl-4-[3-(methylsulfonyl)propoxy]-3-biphenylyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid;(S)-2-(6-((2,6-Dimethyl-4-(3-(methylsulfonyl)propoxy)-[1,1-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid;TAK-875, >=98%;Fasiglifam. CAS No. 1000413-72-8. Molecular formula: C29H32O7S. Mole weight: 524.62518. Purity: 99%+. IUPACName: 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]aceticacid. Canonical SMILES: CC1=CC(=CC(=C1C2=CC(=CC=C2)COC3=CC4=C(C=C3)C(CO4)CC(=O)O)C)OCCCS(=O)(=O)C. Density: 1.252. Product ID: ACM1000413728. Alfa Chemistry ISO 9001:2015 Certified. Categories: TAK375. |  |
Our database is helping our users find suppliers everyday.
